Skip to main content

Advertisement

SpringerLink
Log in

Annals of Surgical Oncology Practice Guidelines Series: Management of Primary Liver and Biliary Tract Cancers

  • Hepatobiliary Tumors
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Primary cancers of the liver and biliary tract are rare and aggressive tumors that often present with locally advanced or metastatic disease. For patients with localized disease amenable to resection, surgery typically offers the best chance at curative-intent therapy. Unfortunately, the incidence of recurrence even after curative-intent surgery remains high. In turn, patients with hepatobiliary cancers commonly require multimodality therapy including a combination of resection, systemic therapy (i.e., targeted therapy, cytotoxic chemotherapy, immunotherapy), and/or loco-regional therapies. With advancements in the field, it is crucial for surgical oncologists to remain updated on the latest guidelines and recommendations for surgical management and optimal patient selection. Given the complex and evolving nature of treatment, this report highlights the latest practice guidelines for the surgical management of hepatobiliary cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Network, N.C.C. Hepatocellular Carcinoma (version 1.2023). 2023. https://www.nccn.org/professionals/physician_gls/pdf/hcc.pdf. Accessed 07 Jan 2023.

  2. LI-RADS, A.C.o.R.C.o. Liver Reporting and Data System (LI-RADS). 2018. (2023). https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS. Accessed 07 Jan 2023.

  3. Reig M, Forner A., Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado A et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76:681–93.

    PubMed  Google Scholar 

  4. Vauthey JN, Lauwers GY, Esnaola NF, Do KA, Belghiti J, Mirza N, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol. 2002;20:1527–36.

    PubMed  Google Scholar 

  5. Abdalla EK, Denys A, Hasegawa K, Leung TW, Makuuchi M, Murthy R, et al. Treatment of large and advanced hepatocellular carcinoma. Ann Surg Oncol. 2008;15:979–85. https://doi.org/10.1245/s10434-007-9727-7.

    Article  PubMed  Google Scholar 

  6. Truty MJ, Vauthey JN. Surgical resection of high-risk hepatocellular carcinoma: patient selection, preoperative considerations, and operative technique. Ann Surg Oncol. 2010;17:1219–25. https://doi.org/10.1245/s10434-010-0976-5.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Kokudo N, Takemura N, Hasegawa K, Takayama T, Kubo S, Shimada M, et al. Clinical practice guidelines for hepatocellular carcinoma: the Japan society of hepatology 2017 (4th JSH-HCC guidelines) 2019 update. Hepatol Res. 2019;49:1109–13.

    PubMed  Google Scholar 

  8. Shi M, Guo RP, Lin XJ, Zhang YQ, Chen MS, Zhang CQ, et al. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. Ann Surg. 2007;245:36–43.

    PubMed  PubMed Central  Google Scholar 

  9. Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul JL, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.

    Google Scholar 

  10. Feng X, Su Y, Zheng S, Xia F, Ma K, Yan J, et al. A double-blinded prospective randomized trial comparing the effect of anatomic versus non-anatomic resection on hepatocellular carcinoma recurrence. HPB. 2017;19:667–74.

    PubMed  Google Scholar 

  11. Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 9900.

  12. Brouquet A, Andreou A, Shindoh J, Vauthey JN. Methods to improve resectability of hepatocellular carcinoma. Recent Results Cancer Res. 2013;190:57–67.

    PubMed  Google Scholar 

  13. Shindoh J, Tzeng CW, Aloia TA, Curley SA, Zimmitti G, Wei SH, et al. Optimal future liver remnant in patients treated with extensive preoperative chemotherapy for colorectal liver metastases. Ann Surg Oncol. 2013;20:2493–500. https://doi.org/10.1245/s10434-012-2864-7.

    Article  PubMed  Google Scholar 

  14. Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN, Abdalla EK. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg. 2007;94:274–86.

    CAS  PubMed  Google Scholar 

  15. Thirunavukarasu P, Aloia TA. Preoperative assessment and optimization of the future liver remnant. Surg Clin North Am. 2016;96:197–205.

    PubMed  Google Scholar 

  16. Rassam F, Olthof PB, van Lienden KP, Bennink RJ, Erdmann JI, Swijnenburg RJ et al. Comparison of functional and volumetric increase of the future remnant liver and postoperative outcomes after portal vein embolization and complete or partial associating liver partition and portal vein ligation for staged hepatectomy (ALPPS). Ann Transl Med. 2020;8:436.

    PubMed  PubMed Central  Google Scholar 

  17. Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Cai J et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16:1344–54.

    CAS  PubMed  Google Scholar 

  18. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–905.

    CAS  PubMed  Google Scholar 

  19. Adjuvant Treatment With Atezolizumab and Bevacizumab May Delay Recurrence After Surgical Resection in Patients With Liver Cancer, 2023, cited 2023. https://www.aacr.org/about-the-aacr/newsroom/news-releases/adjuvant-treatment-with-atezolizumab-and-bevacizumab-may-delay-recurrence-after-surgical-resection-in-patients-with-liver-cancer/#:~:text=%E2%80%93%20Adjuvant%20therapy%20with%20atezolizumab%20. Accessed 07 Jan 2023.

  20. Brown ZJ, Tsilimigras DI, Ruff SM, Mohseni A, Kamel IR, Cloyd JM, et al. Management of hepatocellular carcinoma: a review. JAMA Surg. 2023;158:410–20.

    PubMed  Google Scholar 

  21. Goyal L, Kongpetch S, Crolley VE, Bridgewater J. Targeting FGFR inhibition in cholangiocarcinoma. Cancer Treat Rev. 2021;95:102170.

    CAS  PubMed  Google Scholar 

  22. Doherty B, Nambudiri VE, Palmer WC. Update on the diagnosis and treatment of cholangiocarcinoma. Curr Gastroenterol Rep. 2017;19:2.

    PubMed  Google Scholar 

  23. Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise. Oncologist. 2016;21:594–9.

    PubMed  PubMed Central  Google Scholar 

  24. Mukkamalla SKR, Mukkamalla SK, Naseri HM, Kim BM, Katz SC, Armenio VA. Trends in incidence and factors affecting survival of patients with cholangiocarcinoma in the United States. J Natl Compr Canc Netw. 2018;16:370–6.

    PubMed  Google Scholar 

  25. Fowler KJ, Potretzke TA, Hope TA, Costa EA, Wilson SR. LI-RADS M (LR-M): definite or probable malignancy, not specific for hepatocellular carcinoma. Abdom Radiol NY. 2018;43:149–57.

    PubMed  Google Scholar 

  26. Valls C, Guma A, Puig I, Sanchez A, Andía E, Serrano T, Figueras J. Intrahepatic peripheral cholangiocarcinoma: CT evaluation. Abdom Imaging. 2000;25:490–6.

    CAS  PubMed  Google Scholar 

  27. Seo N, Kim DY, Choi JY. Cross-sectional imaging of intrahepatic cholangiocarcinoma: development, growth, spread, and prognosis. AJR Am J Roentgenol. 2017;209:W64-75.

    PubMed  Google Scholar 

  28. Fábrega-Foster K, Ghasabeh MA, Pawlik TM, Kamel IR. Multimodality imaging of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2017;6:67–78.

    PubMed  PubMed Central  Google Scholar 

  29. Jeong HT, Kim MJ, Chung YE, Choi JY, Park YN, Kim KW. Gadoxetate disodium-enhanced MRI of mass-forming intrahepatic cholangiocarcinomas: imaging-histologic correlation. AJR Am J Roentgenol. 2013;201:W603–11.

    PubMed  Google Scholar 

  30. Kang Y, Lee JM, Kim SH, Han JK, Choi BI.. Intrahepatic mass-forming cholangiocarcinoma: enhancement patterns on gadoxetic acid-enhanced MR images. Radiology. 2012;264:751–60.

    PubMed  Google Scholar 

  31. Péporté AR, Sommer WH, Nikolaou K, Reiser MF, Zech CJ. Imaging features of intrahepatic cholangiocarcinoma in Gd-EOB-DTPA-enhanced MRI. Eur J Radiol. 2013;82:e101–6.

    PubMed  Google Scholar 

  32. Tao LY, Cai L, He XD, Liu W, Qu Q. Comparison of serum tumor markers for intrahepatic cholangiocarcinoma and hepatocellular carcinoma. Am Surg. 2010;76:1210–3.

    PubMed  Google Scholar 

  33. Moro A, Mehta R, Sahara K, Tsilimigras DI, Paredes AZ, Farooq A, Hyer JM, et al. The impact of preoperative CA19-9 and CEA on outcomes of patients with intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2020;27:2888–901.

    PubMed  Google Scholar 

  34. Network, N.C.C. Biliary Tract Cancers (version 2.2023), cited 2023. https://www.nccn.org/professionals/physician_gls/pdf/btc.pdf. Accessed 07 Jan 2023.

  35. EASL-ILCA Clinical practice guidelines on the management of intrahepatic cholangiocarcinoma. J Hepatol. 2023;79:181–208.

  36. Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, Pawlik TM, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60:1268–89.

    PubMed  Google Scholar 

  37. Spolverato G, Vitale A, Cucchetti A, Popescu I, Marques HP, Aldrighetti L, Gamblin TC, et al. Can hepatic resection provide a long-term cure for patients with intrahepatic cholangiocarcinoma? Cancer. 2015;121:3998–4006.

    PubMed  Google Scholar 

  38. D’Angelica M, Fong Y, Weber S, Gonen M, DeMatteo RP, Conlon K, et al. The role of staging laparoscopy in hepatobiliary malignancy: prospective analysis of 401 cases. Ann Surg Oncol. 2003;10:183–9.

    CAS  PubMed  Google Scholar 

  39. Goere D,Wagholikar GD, Pessaux P, Carrère N, Sibert A, Vilgrain V, et al. Utility of staging laparoscopy in subsets of biliary cancers : laparoscopy is a powerful diagnostic tool in patients with intrahepatic and gallbladder carcinoma. Surg Endosc. 2006;20:721–5.

    CAS  PubMed  Google Scholar 

  40. Italian Clinical Practice Guidelines on Cholangiocarcinoma: part II. Treatment. Dig Liver Dis. 2020;52:1430-42.

  41. Zhang X, Cai Y, Xiong X, Liu A, Zhou R, You Z, Li F, et al. Comparison of current guidelines and consensus on the management of patients with cholangiocarcinoma: 2022 update. Intractable Rare Dis Res. 2022;11:161–72.

    PubMed  PubMed Central  Google Scholar 

  42. Lamarca A, Santos‐Laso A, Utpatel K, La Casta A, Stock S, Forner A, Adeva J, et al. Liver metastases of intrahepatic cholangiocarcinoma: implications for an updated staging system. Hepatology. 2021;73:2311–25.

    PubMed  Google Scholar 

  43. Mazzaferro V, Gorgen A, Roayaie S, dit Busset MD, Sapisochin G, et al. Liver resection and transplantation for intrahepatic cholangiocarcinoma. J Hepatol. 2020;72:364–77.

    PubMed  Google Scholar 

  44. Si A, Li J, Yang Z, Xia Y, Yang T, Lei Z, Cheng Z, et al. Impact of anatomical versus non-anatomical liver resection on short- and long-term outcomes for patients with intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2019;26:1841–50. https://doi.org/10.1245/s10434-019-07260-8.

    Article  PubMed  Google Scholar 

  45. Zhang X-F, Bagante F, Chakedis J, Moris D, Beal EW, Weiss M, et al. Perioperative and long-term outcome for intrahepatic cholangiocarcinoma: impact of major versus minor hepatectomy. J Gastrointest Surg. 2017;21:1841–50.

    PubMed  Google Scholar 

  46. Nakagohri T, Asano T, Kinoshita H, Kenmochi T, Urashima T, Miura F, Ochiai T, et al. Aggressive surgical resection for hilar-invasive and peripheral intrahepatic cholangiocarcinoma. World J Surg. 2003;27:289–93.

    PubMed  Google Scholar 

  47. Konstadoulakis MM, Roayaie S, Gomatos IP, Labow D, Fiel MI, Miller CM, et al. Fifteen-year, single-center experience with the surgical management of intrahepatic cholangiocarcinoma: operative results and long-term outcome. Surgery. 2008;143:366–74.

    PubMed  Google Scholar 

  48. Paik KY, Jung JC, Heo JS, Choi SH, Choi DW, Kim YI. What prognostic factors are important for resected intrahepatic cholangiocarcinoma? J Gastroenterol Hepatol. 2008;23:766–70.

    PubMed  Google Scholar 

  49. Lang H, Sotiropoulos GC, Sgourakis G, Schmitz KJ, Paul A, Hilgard P, et al. Operations for intrahepatic cholangiocarcinoma: single-institution experience of 158 patients. J Am Coll Surg. 2009;208:218–28.

    PubMed  Google Scholar 

  50. Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakashima A, Kondo N, et al. Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma. Ann Surg Oncol. 2011;18:651–8. https://doi.org/10.1245/s10434-010-1325-4.

    Article  PubMed  Google Scholar 

  51. Ribero D, Pinna AD, Guglielmi A, Ponti A, Nuzzo G, Giulini SM, et al. Surgical approach for long-term survival of patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis of 434 patients. Arch Surg. 2012;147:1107–13.

    PubMed  Google Scholar 

  52. Vogel A, Bridgewater J, Edeline J, Kelley RK, Klümpen HJ, Malka D, et al. Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:127–40.

    CAS  PubMed  Google Scholar 

  53. Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67:93–9.

  54. Zhang XF, Xue F, Dong DH, Weiss M, Popescu I, Marques HP, Aldrighetti L, et al. Number and station of lymph node metastasis after curative-intent resection of intrahepatic cholangiocarcinoma impact prognosis. Ann Surg. 2021;274:e1187–95.

    PubMed  Google Scholar 

  55. Buell JF, Cherqui D, Geller DA, O’rourke N, Iannitti D, Dagher I, et al. The international position on laparoscopic liver surgery: the Louisville Statement, 2008. Ann Surg. 2009;250:825–30.

    PubMed  Google Scholar 

  56. Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, Anthony A, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20:663–73.

    CAS  PubMed  Google Scholar 

  57. Bridgewater J, Fletcher P, Palmer DH, Malik HZ, Prasad R, Mirza D, et al. Long-term outcomes and exploratory analyses of the randomized phase III BILCAP study. J Clin Oncol. 2022;40:2048–57.

    PubMed  Google Scholar 

  58. Shroff RT, Kennedy EB, Bachini M, Bekaii-Saab T, Crane C, Edeline J, et al. Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline. J Clin Oncol. 2019;37:1015–27.

    PubMed  Google Scholar 

  59. Edeline J, Benabdelghani M, Bertaut A, Watelet J, Hammel P, Joly JP, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J Clin Oncol. 2019;7:658–67.

    Google Scholar 

  60. Ebata T, Hirano S, Konishi M, Uesaka K, Tsuchiya Y, Ohtsuka M, et al. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg. 2018;105:192–202.

    CAS  PubMed  Google Scholar 

  61. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–81.

    CAS  PubMed  Google Scholar 

  62. Oh D-Y, Ruth He A, Qin S, Chen LT, Okusaka T, Vogel A, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. N Engl J Med Evid. 2022;1:EVIDoa2200015.

    Google Scholar 

  63. Maithel SK, Keilson JM, Cao HS, Rupji M, Mahipal A, Lin BS, et al. NEO-GAP: a single-arm, phase iI feasibility trial of neoadjuvant gemcitabine, cisplatin, and nab-paclitaxel for resectable, high-risk intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2023. https://doi.org/10.1245/s10434-023-13809-5.

    Article  PubMed  Google Scholar 

  64. Akateh C, Akateh C, Ejaz AM, Pawlik TM, Cloyd JM. Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma. World J Hepatol. 2020;12:693–708.

    PubMed  PubMed Central  Google Scholar 

  65. Cardinale V, Semeraro R, Torrice A, Gatto M, Napoli C, Bragazzi MC, et al. Intra-hepatic and extra-hepatic cholangiocarcinoma: new insight into epidemiology and risk factors. World J Gastrointest Oncol. 2010;2:407–16.

    PubMed  PubMed Central  Google Scholar 

  66. Wronka KM, Grąt M, Stypułkowski J, Bik E, Patkowski W, Krawczyk M, et al. Relevance of preoperative hyperbilirubinemia in patients undergoing hepatobiliary resection for hilar cholangiocarcinoma. J Clin Med. 2019;8:458.

    CAS  PubMed  PubMed Central  Google Scholar 

  67. Vogel A, Bridgewater J, Edeline J, Kelley RK, Klümpen HJ, Malka D, et al. Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment, and follow-up. Ann Oncol. 2023;34:127–40.

    CAS  PubMed  Google Scholar 

  68. Dumonceau JM, Tringali A, Blero D, Devière J, Laugiers R, Heresbach D, et al. Endoscopic biliary stenting: indications, choice of stents, and results: European society of gastrointestinal endoscopy (ESGE) clinical guideline–updated October 2017. Endoscopy. 2018;50:910–30.

    PubMed  Google Scholar 

  69. Mansour JC, Aloia TA, Crane CH, Heimbach JK, Nagino M, Vauthey JN, et al. Hilar cholangiocarcinoma: expert consensus statement. HPB Oxford. 2015;17:691–9.

    PubMed  PubMed Central  Google Scholar 

  70. Uemura K, Murakami Y, Satoi S, Sho M, Motoi F, Kawai M, et al. Impact of preoperative biliary drainage on long-term survival in resected pancreatic ductal adenocarcinoma: a multicenter observational study. Ann Surg Oncol. 2015;22(Suppl 3):S1238–46. https://doi.org/10.1245/s10434-015-4618-9.

    Article  PubMed  Google Scholar 

  71. Strom TJ, Klapman JB, Springett GM, Meredith KL, Hoffe SE, Choi J, et al. Comparative long-term outcomes of upfront resected pancreatic cancer after preoperative biliary drainage. Surg Endosc. 2015;29:3273–81.

    PubMed  PubMed Central  Google Scholar 

  72. Miura F, Sano K, Wada K, Shibuya M, Ikeda Y, Takahashi K, et al. Prognostic impact of type of preoperative biliary drainage in patients with distal cholangiocarcinoma. Am J Surg. 2017;214:256–61.

    PubMed  Google Scholar 

  73. Tieu AH, Kumbhari V, Jakhete N, Onyimba F, Patel Y, Shin EJ, et al. Diagnostic and therapeutic utility of SpyGlass(®) peroral cholangioscopy in intraductal biliary disease: single-center, retrospective, cohort study. Dig Endosc. 2015;27:479–85.

    PubMed  Google Scholar 

  74. Pereira P, Vilas-Boas F, Peixoto A, Andrade P, Lopes J, Macedo G. How SpyGlass™ may impact endoscopic retrograde cholangiopancreatography practice and patient management. GE Port J Gastroenterol. 2018;25:132–7.

    PubMed  Google Scholar 

  75. Network O. P.a.T. OPTN Policies. 2023, cited 2023. https://optn.transplant.hrsa.gov/media/eavh5bf3/optn_policies.pdf. Accessed 07 Jan 2023.

  76. Banales JM, Marin JJ, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17:557–88.

    PubMed  PubMed Central  Google Scholar 

  77. Bhutiani N, Scoggins CR, McMasters KM, Ethun CG, Poultsides GA, Pawlik TM, et al. The impact of caudate lobe resection on margin status and outcomes in patients with hilar cholangiocarcinoma: a multi-institutional analysis from the US Extrahepatic Biliary Malignancy Consortium. Surgery. 2018;163:726–31.

    PubMed  Google Scholar 

  78. Wahab MA, Sultan AM, Salah T, Fathy O, Elebidy G, Elshobary M, et al. Caudate lobe resection with major hepatectomy for central cholangiocarcinoma: is it of value? Hepatogastroenterology. 2012;59:321–4.

    PubMed  Google Scholar 

  79. Weber SM, Ribero D, O'Reilly EM, Kokudo N, Miyazaki M, Pawlik TM. Intrahepatic cholangiocarcinoma: expert consensus statement. HPB Oxford. 2015;17:669–80.

    PubMed  PubMed Central  Google Scholar 

  80. Heimbach JK, Gores GJ, Haddock MG, Alberts SR, Nyberg SL, Ishitani MB, et al. Liver transplantation for unresectable perihilar cholangiocarcinoma. Semin Liver Dis. 2004;24:201–7.

    PubMed  Google Scholar 

  81. Breuer E, Mueller M, Doyle MB, Yang L, Murad SD, Anwar IJ, et al. Liver transplantation as a new standard of care in patients with perihilar cholangiocarcinoma? Results from an international benchmark study. Ann Surg. 2022;276:846–53.

    PubMed  Google Scholar 

  82. Ethun CG, Lopez-Aguiar AG, Anderson DJ, Adams AB, Fields RC, Doyle MB, et al. Transplantation versus resection for hilar cholangiocarcinoma: an argument for shifting treatment paradigms for resectable disease. Ann Surg. 2018;267:797–805.

    PubMed  Google Scholar 

  83. Park JH, Choi EK, Do Ahn S, Lee SW, Song SY, Yoon SM, et al. Postoperative chemoradiotherapy for extrahepatic bile duct cancer. Int J Radiat Oncol Biol Phys. 2011;79:696–704.

    CAS  PubMed  Google Scholar 

  84. Borghero Y, Crane CH, Szklaruk J, Oyarzo M, Curley S, Pisters PW, et al. Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. Ann Surg Oncol. 2008;15:3147–56.

    PubMed  Google Scholar 

  85. Kim TH, Han SS, Park SJ, Lee WJ, Woo SM, Moon SH, et al. Role of adjuvant chemoradiotherapy for resected extrahepatic biliary tract cancer. Int J Radiat Oncol Biol Phys. 2011;81:e853–9.

    PubMed  Google Scholar 

  86. Lim KH, Oh DY, Chie EK, Jang JY, Im SA, Kim TY, et al. Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: which is better in patients with radically resected extrahepatic biliary tract cancer? A non-randomized, single-center study. BMC Cancer. 2009;9:345.

    PubMed  PubMed Central  Google Scholar 

  87. Nelson JW, Ghafoori AP, Willett CG, Tyler DS, Pappas TN, Clary BM, et al. Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys. 2009;73:148–53.

    CAS  PubMed  Google Scholar 

  88. Hughes MA, Frassica DA, Yeo CJ, Riall TS, Lillemoe KD, Cameron JL, et al. Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int J Radiat Oncol Biol Phys. 2007;68:178–82.

    CAS  PubMed  Google Scholar 

  89. Ben-Josef E, Guthrie KA, El-Khoueiry AB, Corless CL, Zalupski MM, Lowy AM, et al. SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol. 2015;33:2617–22.

    CAS  PubMed  Google Scholar 

  90. Gómez-España MA, Montes AF, Garcia-Carbonero R, Mercadé TM, Maurel J, Martín AM, et al. SEOM clinical guidelines for pancreatic and biliary tract cancer (2020). Clin Transl Oncol. 2021;23:988–1000.

    PubMed  PubMed Central  Google Scholar 

  91. Hawkins WG, DeMatteo RP, Jarnagin WR, Ben-Porat L, Blumgart LH, Fong Y. Jaundice predicts advanced disease and early mortality in patients with gallbladder cancer. Ann Surg Oncol. 2004;11:310–5. https://doi.org/10.1245/aso.2004.03.011.

    Article  PubMed  Google Scholar 

  92. Dasari BVM, Ionescu MI, Pawlik TM, Hodson J, Sutcliffe RP, Roberts KJ, et al. Outcomes of surgical resection of gallbladder cancer in patients presenting with jaundice: a systematic review and meta-analysis. J Surg Oncol. 2018;118:477–85.

    PubMed  Google Scholar 

  93. Nishio H, Ebata T, Yokoyama Y, Igami T, Sugawara G, Nagino M. Gallbladder cancer involving the extrahepatic bile duct is worthy of resection. Ann Surg. 2011;253:953–60.

    PubMed  Google Scholar 

  94. Regimbeau JM, Fuks D, Bachellier P, Le Treut YP, Pruvot FR, Navarro F, et al. Prognostic value of jaundice in patients with gallbladder cancer by the AFC-GBC-2009 study group. Eur J Surg Oncol. 2011;37:505–12.

    CAS  PubMed  Google Scholar 

  95. Aloia TA, Járufe N, Javle M, Maithel SK, Roa JC, Adsay V, et al. Gallbladder cancer: expert consensus statement. HPB Oxford. 2015;17:681–90.

    PubMed  PubMed Central  Google Scholar 

  96. Fuks D, Fuks D, Regimbeau JM, Le Treut YP, Bachellier P, Raventos A, Pruvot FR, et al. Incidental gallbladder cancer by the AFC-GBC-2009 study group. World J Surg. 2011;35:1887–97.

    PubMed  Google Scholar 

  97. Lee SE, Jang JY, Lim CS, Kang MJ, Kim SW. Systematic review on the surgical treatment for T1 gallbladder cancer. World J Gastroenterol. 2011;17:174–80.

    PubMed  PubMed Central  Google Scholar 

  98. Qadan M, Kingham TP. Technical aspects of gallbladder cancer surgery. Surg Clin North Am. 2016;96:229–45.

    PubMed  PubMed Central  Google Scholar 

  99. Ethun CG, Postlewait LM, Le N, Pawlik TM, Buettner S, Poultsides G, et al. Association of optimal time interval to re-resection for incidental gallbladder cancer with overall survival: a multi-institution analysis from the U.S. Extrahepatic biliary malignancy consortium. JAMA Surg. 2017;152:143–9.

    PubMed  PubMed Central  Google Scholar 

  100. Soares KC, Kamel I, Cosgrove DP, Herman JM, Pawlik TM. Hilar cholangiocarcinoma: diagnosis, treatment options, and management. Hepatobiliary Surg Nutr. 2014;3:18–34.

    PubMed  PubMed Central  Google Scholar 

Download references

Funding

There was no external funding for this manuscript.

Author information

Authors and Affiliations

  1. Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA

    Samantha M. Ruff MD, Jordan M. Cloyd MD & Timothy M. Pawlik MD, PhD, MPH, MTS, MBA

Authors
  1. Samantha M. Ruff MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jordan M. Cloyd MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Timothy M. Pawlik MD, PhD, MPH, MTS, MBA
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Timothy M. Pawlik MD, PhD, MPH, MTS, MBA.

Ethics declarations

Disclosure

There are no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ruff, S.M., Cloyd, J.M. & Pawlik, T.M. Annals of Surgical Oncology Practice Guidelines Series: Management of Primary Liver and Biliary Tract Cancers. Ann Surg Oncol 30, 7935–7949 (2023). https://doi.org/10.1245/s10434-023-14255-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-023-14255-z

Keywords

Search

Navigation